ClinicalTrials.gg
RecruitingNCT07434947REHAB-CBNPCUpdated Oct 13, 2026

Study of Three Endpoints to Assess the Benefit of Rehabilitation in Patients With Advanced Non-small Cell Lung Cancer Controlled After at Least 6 Months of Systemic Treatment

An observational study in Lung Cancer (NSCLC), sponsored by University Hospital, Grenoble. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's title name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Grenoble · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 13, 2026Now RecruitingStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
63
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France — 170 open to participants now, 327 under way, 105 of them phase 3. Carcinoma, Non-Small-Cell Lung · France.

Planned enrollment
82nd of 104
63 · median 151
Started
2026
with 34 others
Observational
104 of 875
26 open now
Primary completion
2027-10
later than 165 of 326 live
Registered
846th of 875
by date

Among the 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France, this one is the 82nd largest by planned enrollment of the 104 observational ones that give a count, is one of 35 that started in 2026, is one of 104 observational ones, reaches primary completion later than 165 of the 326 other live ones, and was the 846th registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

170 of the 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France are open now. Recruiting first, the newest first:

164 more — sign in →

All 170 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France, or all of them as a file.
02

Study summary

The objective of this study is to identify an outcome that is relevant for assessing the benefit of rehabilitation in patients with advanced or metastatic non-small cell lung cancer whose disease has been stable or responding for at least 6 months with systemic treatment.

Many people living with lung cancer experience asthenia, which reduces daily activity, independence, and quality of life.

Regular physical activity (PA) is recommended for the management of all chronic diseases, including cancer. PA can be done independently by the patient or supervised by adapted physical activity instructors (EAPA) at home or in a day hospital (HDJ) in medical and rehabilitation care departments (SMR), where it is covered by social security.

Rehabilitation program and physical activity may help improve strength, function, and social participation, for patients with non-small cell lung cancer .

In this study, patients will participate in a 3-month rehabilitation program. We will measure quality of life, hand grip strength, and the Five Times Sit to Stand Test, before and after the program. Other measures will include daily step counts, nutrition, overall health status, continuation of cancer treatment, program adherence, and participant satisfaction.

About 63 participants will be recruited in several hospitals, including CHUGA, CHMS and CHANGE. This patients will be able to choose a program that suits them and is available as part of they care. We are expecting 50 patients to participate in one of the rehabilitation program.

The main goal is to identify the most useful outcomes to assess in future studies that will compare different rehabilitation approaches for people with lung cancer.

Read the detailed description

This study (REHAB-CBNPC) is a prospective, multicenter, observational trial coordinated by Pr. Anne-Claire Toffart and sponsored by CHU Grenoble Alpes. It aims to identify the most relevant outcome measure to evaluate the benefit of rehabilitation programs in patients with advanced or metastatic non-small cell lung cancer whose disease remains controlled after at least 6 months of systemic treatment.

Regular physical activity is recommended for people with chronic diseases, including cancer. In non-small cell lung cancer, preoperative and postoperative rehabilitation has demonstrated benefits, particularly in patients with impaired respiratory function. However, evidence regarding rehabilitation in patients with advanced or metastatic non-small cell lung cancer whose disease is controlled at distance from initial treatment remains scarce. These patients frequently experience cancer-related fatigue, reduced activity levels, and impaired quality of life, highlighting the need for adapted rehabilitation approaches.

Eligible participants will be adults with locally advanced or metastatic non-small cell lung cancer, ECOG-PS 0-2, and a self-reported functional limitation, recruited from three centers in the Auvergne-Rhône-Alpes region of France (CHU Grenoble Alpes, CH Chambéry, CH Annecy-Genevois). Rehabilitation programs will be delivered according to local practice, either in specialized rehabilitation units (SMR), hospital-based day programs, or at home with adapted physical activity providers.

Approximately 63 patients will be enrolled to participate in a study on physical activity, they will be recruited at one of the participating centers during consultations with their referring oncologist. anticipating that about 50 will complete a rehabilitation program. If they meet all the inclusion criteria and do not have any exclusion criteria, they will be offered the opportunity to participate in a study on physical activity. They will then have the choice of whether or not to participate.

If they agree, they will be able to choose a rehabilitation program that suits them and is available as part of their care.

Each participant will be followed for 3 months, and data will be collected through electronic case report forms (REDCap).

This exploratory study will evaluate three main outcomes before and after a 3-month rehabilitation program: quality of life (EQ-5D-5L), hand grip strength, and the five-times sit-to-stand test. The study will also assess feasibility and sensitivity to change of additional measures, including step counts, physical activity and sedentary behavior (ONAPS-PAQ), nutritional status, performance status (ECOG-PS), continuation of systemic treatment, adherence to the program, causes of non-participation, and patient satisfaction (CSQ-8).

Quantitative variables will be described by their means and standard deviations, as well as medians and interquartile ranges. Qualitative variables will be described by the associated numbers and percentages. Any normality will be verified graphically.

The expected outcomes include a better understanding of feasibility, adherence, and sensitivity of candidate endpoints. Results will inform the selection of the most appropriate primary endpoint for future randomized controlled trials comparing rehabilitation strategies in advanced non-small cell lung cancer

03

Conditions studied

  • Lung Cancer (NSCLC)

Browse trials for

Keywords

  • readaptation
  • Physical activity
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's planned enrollment of 63 is below the median of 160 across 1,151 observational studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes patients with metastatic or locally advanced non-small cell lung cancer whose tumor disease is controlled and who are at least 6 months post-treatment with any anti-tumor therapy.

They must have a complaint related to physical activity.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients treated for NSCLC at CHUGA, CHMS, or CHANGE
  • Locally advanced or NSCLC
  • Tumor disease controlled for at least 6 months following any type of anti-tumor treatment
  • Performance Status 0 to 2
  • Patient reporting functional complaints related to physical activity
  • Covered by the national health insurance system

Exclusion criteria

Exclusion Criteria:

  • Initial management of the tumor disease started ≥ 2 years ago
  • Residual toxicity of grade ≥ 2
  • Estimated less than 6 months (at the discretion of the investigator)
  • Patient with an absolute to physical activity at the time of consultation (e.g., unstable angina; acute intercurrent event...)
  • Subject currently in an exclusion period from another study or participating in an interventional study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
63 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with metastatic or locally advanced non-small cell lung cancer.

    The study population includes patients with metastatic or locally advanced non-small cell lung cancer whose tumour disease is controlled and who are at least 6 months into any anti-tumour treatment. They must have a functional complaint concerning physical activity.

07

What researchers measure

Primary outcomes

  1. Hand-grip

    Hand grip strength is measured with a hand dynamometer. It is a measure of grip strength in kilograms, which is associated with muscle mass. The subject holds the device in one hand, usually with the elbow at 90° and the wrist straight. On signal, they squeeze as hard as possible for a few seconds. The test is repeated 2-3 times for each hand, and the best or average value is recorded.

    Time frame: periprocedural of the exercise rehabilitation program

  2. EQ5DL Score

    EQ5DL is a score about life quality. It includes two part: The first part assesses health in five dimensions, each of which has five levels of response (no problems, slight problems, moderate problems, severe problems, extreme problems/unable to). This part of the EQ-5D questionnaire provides a descriptive profile that can be used to generate a health state profile. Each health state can potentially be assigned a summary index score based on societal preference weights for the health state. Health state index scores generally range from less than 0 (where 0 is the value of a health state equivalent to dead; negative values representing values as worse than dead) to 1 (the value of full health), with higher scores indicating higher health utility. The second part consists of a visual analogue scale (VAS) on which rates his/her perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).

    Time frame: periprocedural of the exercise rehabilitation program

  3. Five Times Sit To Stand

    The subject sits on a chair , with arms crossed over the chest. On the tester's signal, the subject stands up fully and sits back down five times as quickly as possible without using the arms for support. The time needed to complete the five repetitions is measured.

    Time frame: periprocedural of the exercise rehabilitation program

Secondary outcomes

  1. ONAPS-PAQ test

    The Onaps-PAQ questionnaire assesses the level of physical activity and sedentary behavior during a typical week for the adult population. It is divided into three parts and 21 questions: activities at work, trips for practical purposes, and leisure or home activities. This questionnaire also assesses sedentary behavior in all areas of life (travel, work, leisure). Patients are considered to be very active, active, or inactive. There are also three levels of sedentary behavior: low, moderate, and high.

    Time frame: periprocedural of the exercise rehabilitation program

  2. ECOG-PS

    It describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.). The ECOG Performance Status Scale measure how the disease impacts a patient's daily living abilities, known to physicians and researchers as a patient's performance status.

    Time frame: periprocedural of the exercise rehabilitation program

  3. CSQ-8

    It is the Client Satisfaction Questionnaire. It will be use to measure and assess consumer satisfaction with health and human services. There are 8 questions, total scores range from 8 to 32, with the higher number indicating greater satisfaction.

    Time frame: through study completion, an average of 3 months

  4. Average number of steps in the previous week (using smartphone app)

    If it's available, on a app, it is the number of steps the week before.

    Time frame: periprocedural of the exercise rehabilitation program

  5. Continuation of oncological treatment

    We will collect information on the patient's cancer treatment: * Same as before rehabilitation * Treatment modified due to tumor progression * Treatment discontinued because no longer indicated (no tumor progression) * Treatment discontinued because of palliative care only

    Time frame: through study completion, an average of 3 months

  6. Weight (in kg)

    Time frame: periprocedural of the exercise rehabilitation program

  7. Reason for refusing/not participating in a program

    If patients agree to participate in the study but do not wish to participate in any rehabilitation program, we will collect the reason for this.

    Time frame: At Baseline

  8. Adherence to the rehabilitation program.

    We will collect data if the patient has completed the entire program until the end (with the possibility of a few sessions not being completed).

    Time frame: through study completion, an average of 3 months

  9. Adverse events

    We will collect adverse events related to the tumor disease (including treatment and cancer itself) or the rehabilitation program, as well as the consequences.

    Time frame: through study completion, an average of 3 months

08

Study locations

1 of 3 sites recruiting
09

References and documents

Publications

  • Gouez M, Perol O, Perol M, Caux C, Menetrier-Caux C, Villard M, Walzer T, Delrieu L, Saintigny P, Marijnen P, Pialoux V, Fervers B. Effect of acute aerobic exercise before immunotherapy and chemotherapy infusion in patients with metastatic non-small-cell lung cancer: protocol for the ERICA feasibility trial. BMJ Open. 2022 Apr 7;12(4):e056819. doi: 10.1136/bmjopen-2021-056819. PubMed 35393316 ↗
  • Catho H, Guigard S, Toffart AC, Frey G, Chollier T, Brichon PY, Roux JF, Sakhri L, Bertrand D, Aguirre C, Gorain S, Wuyam B, Arbib F, Borel JC. What are the barriers to the completion of a home-based rehabilitation programme for patients awaiting surgery for lung cancer: a prospective observational study. BMJ Open. 2021 Feb 10;11(2):e041907. doi: 10.1136/bmjopen-2020-041907. PubMed 33568371 ↗
10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2027, 17 months after the start.

Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 17 months is below that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

Start moved twice since we started tracking on Sep 25, 2026: Mar 2026 → Apr 2026, last on Oct 13, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2027 → Oct 2027, on Oct 13, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2027 → Oct 2027, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Feb 27, 2026
StartActual
Apr 15, 2026was Mar 2026
Primary completionEst.
Oct 14, 2027was Aug 2027
CompletionEst.
Oct 14, 2027was Aug 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
1 site added, 1 site removed. 2 sites changed recruiting status (2 now not yet recruiting)
Show 2 sites
  • Centre Hospitalier Annecy Genevois · Annecy, Franceno status→Not yet recruiting
  • CHU Grenoble Alpes · Grenoble, Franceno status→Not yet recruiting
Show site
  • CH Métropole Savoie · Chambéry, France
Show 1 removed
  • CH Métropole Savoie · Chambéry, France
Oct 2, 2026
Start date
Mar 2026→Apr 15, 2026
moved 2 times, Oct 2, 2026 – Oct 13, 2026
Primary completion
Aug 2027→Oct 14, 2027
Oct 13, 2026
Study completion
Aug 2027→Oct 14, 2027
Oct 13, 2026
Show all 2 updates
  1. Oct 13, 2026
    Start date Feb 20, 2026→Apr 15, 2026
    Primary completion Aug 2027→Oct 14, 2027
    Study completion Aug 2027→Oct 14, 2027
    + 1 other change: verification date
  2. Oct 2, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed. 2 sites changed recruiting status (2 now not yet recruiting)
    Show 2 sites
    • Centre Hospitalier Annecy Genevois · Annecy, Franceno status→Not yet recruiting
    • CHU Grenoble Alpes · Grenoble, Franceno status→Not yet recruiting
    Show site
    • CH Métropole Savoie · Chambéry, France
    Show 1 removed
    • CH Métropole Savoie · Chambéry, France
    Start date Mar 2026→Feb 20, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07434947
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Apr 15, 2026
Primary completion
Oct 14, 2027 (estimated)
Completion
Oct 14, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Anne-Claire TOFFART
Contact
AToffart@chu-grenoble.fr
33 +(0)4 76 76 68 31
Etienne FOULON
Contact
EFoulon1@chu-grenoble.fr
Anne-Claire TOFFART
principal investigator · CHU Grenoble Alpes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion